期刊文献+

抗PTD-bcr/abl单克隆抗体的制备及鉴定 被引量:2

Preparation and characterization of the monoclonal antibodies to PTD-bcr/abl
下载PDF
导出
摘要 目的:制备单克隆抗体(mAb)并初步用于PTD-bcr/abl融合蛋白的研究,为慢性粒细胞白血病的免疫治疗提供实验依据。方法:在大肠杆菌中表达PTD-bcr/abl融合蛋白,用所获得的蛋白免疫BALB/c小鼠,常规收集小鼠脾细胞与Sp2/0细胞融合,筛选杂交瘤细胞株的阳性克隆,并对其进行一系列鉴定。结果:(1)表达PTD-bcr/abl融合蛋白;(2)制备了抗PTD-bcr/abl融合蛋白mAb;(3)用mAb以多种方法检测PTD-bcr/abl融合蛋白,证实此抗体效价高,特异性强。结论:此抗体可用于PTD-bcr/abl融合蛋白的进一步研究。 AIM: To Preparation and characterization the monoclonal antibody (mAb) to PTD-bcr/abl fusion protein. METHODS: The PTD-bcr/abl fusion protein was expressed in E. coli. BALB/c mice were immunized with specific PTD-bcr/abl. The splenic cells of the mice were fused with Sp2/0 mouse myeloma cells. The hybridoma culture supernatants were screened by indirect ELISA. The property of the antibody was identified by Western blot and immunohistochemistry. RESULTS: The PTD-bcr/abl fusion protein and its mAb were obtained, mAb against PTD-bcr/abl displayed strong specifllity and high affinity. CONCLUSION: An anti-PTD-bcr/abl fusion protein mAb with high affinity was abtained, which could be applied to the research of PTD-bcr/abl.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2008年第5期488-490,共3页 Chinese Journal of Cellular and Molecular Immunology
基金 第四军医大学基金资助项目(CX02A023)
关键词 PTD-bcr/abl融合蛋白 单克隆抗体 制备 PTD-bcr/abl monoclonal antibody Preparation
  • 相关文献

参考文献6

  • 1梁英民,孙强,蒋姗姗,陈萍,王冀姝,刘利,韩骅.PTD-bcr/abl融合癌蛋白片段的表达及其跨膜转运[J].细胞与分子免疫学杂志,2001,17(4):377-380. 被引量:8
  • 2梁英民,孙强,蒋姗姗,王冀姝,吴绒丽,陈萍,刘利,韩骅.蛋白转导结构域-bcr/abl融合基因的构建和表达[J].中华血液学杂志,2002,23(1):5-8. 被引量:8
  • 3Schwarze SR, Ho A, Vocero-Akbani A, et al. In vivo protein transduction : delivery of a biologically active protein into the mouse [ J ]. Science, 1999, 285(5433): 1569- 1572.
  • 4Tadjine M, Mittal KR, Bourdon S, et al. Production and characterization of routine monoclonal antibodies against Haemophilus parasuis and study of their protective role in mice[J]. Microbiology, 2004, 150 (12) : 3935 -3945.
  • 5Nieda M, Nicol A, Kikuchi A, et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8^+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia [ J ]. Blood, 1998, 91(3): 977-983.
  • 6Yotnda P, Firat H, Garcia-Poons F, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia[ J]. J Clin Invest, 1998, 101 (10) : 2290 -2296.

二级参考文献11

  • 1Osman Y,Leukemia,1999年,13卷,2期,166页
  • 2Ten-Bosch GJ,Kessler JH,Joosten AM,et al.A bcr-abl oncoprotein p210 b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct[].Blood.1999
  • 3Buzyn A,Petit F,Ostankovitch M,et al.Membrane-bound Fas(Apo1/CD95 ) ligand on leukemic cells: a mechanism of tumor immune escape in leukemia patients[].Blood.1999
  • 4Schwarze SR,Ho A,Vocero-Akbani A,et al.In vivo protein transduction: delivery of a biologically active protein into the mouse[].Science.1999
  • 5Shtivelman E,Lifshitz B,Gale RP,et al.Fused transcript of abl and bcr genes in chronic myelogenous leukaemia[].Nature.1985
  • 6Vives E,Brodin P,Lebleu B.A truncated HIV-1 TAT protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus[].Journal of Biological Chemistry.1997
  • 7Norbury LC,Clark RE,Christmas SE.b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia[].British Journal of Haematology.2000
  • 8Coleman S,Throp D,Fisher J,et al.Cytokine enhancement of immunogenicity in chronic myeloid leukemia[].Leukemia.1997
  • 9Nieda M,Nicol A,Kikuchi A,et al.Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia[].Blood.1998
  • 10Yotnda P,Firat H,Garcia-Pons F,et al.Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia[].The Journal of Clinical Investigation.1998

共引文献11

同被引文献27

  • 1卡尔尼克BW.禽病学[M].9版.北京:北京农业出版社,1991:432-436.
  • 2Ma Mayo. A summary of taxonomic changes recently approved by ICTV[J]. Archives of Virology, 2002, 147(8): 1655-1663.
  • 3Steward M, Vipond I B, Millar N S, et al. RNA editing in newcastle disease virus[J]. The Journal of General Virology, 1993, 74( 12): 2539-2547.
  • 4Kho C L, Tan Ws, Yusoff K. Production of the nucleocapsid protein of newcastle disease virus in Escherichia coli and its assembly of into ring-like and nueleocapsid-like particles[J]. Journal of Microbiology, 2001, 39(4): 293-299.
  • 5Hamaguchi M, Yoshida T, Nishikawa K, et al. Transcriptive complex of newcastle disease virus. I. both L and P proteins are required to constitute an active complex[J]. Virology, 1983, 128 (1): 105-117.
  • 6Makkay A M, Krell P J, Nagy E. Antibody detection-based differential elisa for NDV-infected or vaccinated chickens versus NDV HN-subunit vaccinated chickens[J]. Veterinary Microbiology, 1999, 66(3): 209-222.
  • 7Russell P H, Griffiths P C, Goswami K K, et al. The characterization of monoclonal antibodies to newcastle disease virus[J]. The Journal of General Virology, 1983, 64(9): 2069-2072.
  • 8Panshin A, Shihmanter E, Weisman Y, et al. Antigenic characterization of the nucleocapsid protein of newcastle disease virus by means of a new panel of monoclonal antibodies[J]. Comparative Immunology Microbiology and Infectious Diseases, 2000, 23(3): 209-220.
  • 9Ahmad-raus R, Ali A M, Tan Ws, et al. Localization of the antigenic sites of newcastle disease virus nucleocapsid using a panel of monoclonal antibodies[J]. Research in Veterinary Science, 2009, 86(1): 174-182.
  • 10Diamanclis M, White NM, Yousef CM. Personalized medicine: marking a new epoch in cancer patient management[J]. Mol Cancer Res, 2010, 8(9):1175-1187.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部